Sign In
Buy IFF
Internationa Flavors & Fragrances Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $1.02 |
| EPS actual | $1.05 |
| EPS Surprise | 2.94% |
| Revenue estimate | 2.522B |
| Revenue actual | 2.694B |
| Revenue Surprise | 6.82% |
| Release date | Aug 05, 2025 |
| EPS estimate | $1.12 |
| EPS actual | $1.15 |
| EPS Surprise | 2.68% |
| Revenue estimate | 2.702B |
| Revenue actual | 2.764B |
| Revenue Surprise | 2.28% |
| Release date | May 06, 2025 |
| EPS estimate | $1.13 |
| EPS actual | $1.20 |
| EPS Surprise | 6.19% |
| Revenue estimate | 2.83B |
| Revenue actual | 2.843B |
| Revenue Surprise | 0.455% |
| Release date | Feb 18, 2025 |
| EPS estimate | $0.83 |
| EPS actual | $0.97 |
| EPS Surprise | 16.87% |
| Revenue estimate | 2.681B |
| Revenue actual | 2.771B |
| Revenue Surprise | 3.34% |
Last 4 Quarters for Internationa Flavors & Fragrances
Below you can see how IFF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 18, 2025 |
| Price on release | $86.45 |
| EPS estimate | $0.83 |
| EPS actual | $0.97 |
| EPS surprise | 16.87% |
| Date | Price |
|---|---|
| Feb 11, 2025 | $85.21 |
| Feb 12, 2025 | $84.68 |
| Feb 13, 2025 | $86.00 |
| Feb 14, 2025 | $85.58 |
| Feb 18, 2025 | $86.45 |
| Feb 19, 2025 | $81.99 |
| Feb 20, 2025 | $80.14 |
| Feb 21, 2025 | $79.89 |
| Feb 24, 2025 | $79.61 |
| 4 days before | 1.46% |
| 4 days after | -7.91% |
| On release day | -5.16% |
| Change in period | -6.57% |
| Release date | May 06, 2025 |
| Price on release | $79.20 |
| EPS estimate | $1.13 |
| EPS actual | $1.20 |
| EPS surprise | 6.19% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $78.46 |
| May 01, 2025 | $77.85 |
| May 02, 2025 | $79.06 |
| May 05, 2025 | $79.15 |
| May 06, 2025 | $79.20 |
| May 07, 2025 | $73.59 |
| May 08, 2025 | $74.08 |
| May 09, 2025 | $73.43 |
| May 12, 2025 | $76.35 |
| 4 days before | 0.94% |
| 4 days after | -3.60% |
| On release day | -7.08% |
| Change in period | -2.69% |
| Release date | Aug 05, 2025 |
| Price on release | $70.62 |
| EPS estimate | $1.12 |
| EPS actual | $1.15 |
| EPS surprise | 2.68% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $71.77 |
| Jul 31, 2025 | $71.03 |
| Aug 01, 2025 | $69.48 |
| Aug 04, 2025 | $70.15 |
| Aug 05, 2025 | $70.62 |
| Aug 06, 2025 | $66.16 |
| Aug 07, 2025 | $64.23 |
| Aug 08, 2025 | $63.56 |
| Aug 11, 2025 | $63.46 |
| 4 days before | -1.60% |
| 4 days after | -10.14% |
| On release day | -6.32% |
| Change in period | -11.58% |
| Release date | Nov 04, 2025 |
| Price on release | $61.49 |
| EPS estimate | $1.02 |
| EPS actual | $1.05 |
| EPS surprise | 2.94% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $63.28 |
| Oct 30, 2025 | $63.13 |
| Oct 31, 2025 | $62.97 |
| Nov 03, 2025 | $62.08 |
| Nov 04, 2025 | $61.49 |
| Nov 05, 2025 | $64.00 |
| Nov 06, 2025 | $62.85 |
| Nov 07, 2025 | $62.00 |
| Nov 10, 2025 | $62.78 |
| 4 days before | -2.83% |
| 4 days after | 2.09% |
| On release day | 4.08% |
| Change in period | -0.798% |
Internationa Flavors & Fragrances Earnings Call Transcript Summary of Q3 2025
IFF reported Q3 2025 results showing resilience in a challenging macro environment: revenue was essentially flat versus a strong prior-year comparable, driven by mid-single-digit growth in Scent and low-single-digit growth in Taste, offsetting weakness in Food Ingredients and short-term pressure in Health & Biosciences (notably North America Health). Adjusted operating EBITDA grew 7% year‑over‑year to $519 million, with margin expansion of 130 basis points to 19.3%. Management reiterated full‑year 2025 guidance: sales of $10.6B–$10.9B and adjusted operating EBITDA of $2.0B–$2.15B, expecting to finish near the low end of the sales growth range (1%–4%) and near the midpoint of the EBITDA growth range (5%–10%). Strategic highlights include continued portfolio optimization (divestitures completed/announced), deleveraging to ~2.5x net debt/EBITDA, a $500M share repurchase authorization, targeted investments in innovation and capacity (DEB technology, new creative and innovation centers, joint venture with Kemira), and ongoing commercial/organizational upgrades in Health & Biosciences to drive recovery in 2H 2026 and into 2027. Management is prioritizing profitability, margin expansion, working capital improvements, and disciplined capital allocation while preparing for incremental growth if end markets normalize.
